SuppreMol appoints industry expert Klaus Schollmeier as CEO
(Thomson Reuters ONE) -
SuppreMol GmbH /
SuppreMol appoints industry expert Klaus Schollmeier as CEO
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Munich, Germany, April 02, 2013: SuppreMol GmbH, a privately held
biopharmaceutical company developing novel therapies for the treatment of
autoimmune diseases, today announced the appointment of Dr. Klaus Schollmeier as
Chief Executive Officer (CEO) of the Company with effect April 1st, 2013. Dr.
Schollmeier succeeds Prof. Dr. Peter Buckel, who resigns as CEO having reached
retirement age.
Dr. Schollmeier has more than 25 years of successful international management
experience in the pharmaceutical and biotech industry as well as in investment
banking. Dr. Schollmeier led Santhera Pharmaceuticals AG as CEO since the
company's foundation in 2004 and acts as Chairman of the Board since October
2011. Previously, he was Managing Director Healthcare / Biotechnology at ING
BHF-Bank. Before this, he spent 16 years in the pharmaceutical industry at BASF,
Knoll and Abbott. His scientific responsibilities included head of
oncology/immunology research at BASF's central laboratories in Germany, and
senior director of biotechnology at BASF Bioresearch Corporation in Cambridge,
US. His business functions included General Manager of BASF Pharma Netherlands
and Vice President and General Manager for Western Europe. Mr. Schollmeier holds
a Ph.D. in Biology from the University of Düsseldorf, Germany.
Dr. Thomas Hecht, Chairman of the Advisory Board of SuppreMol GmbH, said: "We
are very pleased to have Dr. Schollmeier joining our Company at a time when
SuppreMol is entering a new and exciting phase. The Company has a very promising
product candidate for the treatment of autoimmune diseases in phase II clinical
development with important clinical and regulatory milestones ahead. Dr.
Schollmeier will bring the necessary experience to the Company to advance
SuppreMol's products towards a BLA (Biologics License Application)." Dr. Hecht
added: "On behalf of the Board I would like to thank Prof. Dr. Peter Buckel for
his long-standing commitment to the success of SuppreMol and his valuable
contributions in building the company over the past years."
"I look forward to leading SuppreMol in the exciting years to come. SuppreMol's
product candidates are based on innovative science and have shown promising data
in early clinical trials," stated Dr. Klaus Schollmeier, the Chief Executive
Officer of SuppreMol GmbH. "I will lead the corporate and commercial development
of SuppreMol in the years to come with the ambition to successfully advance the
key assets, in particular the lead program SM101."
About SuppreMol
SuppreMol GmbH is a privately held biopharmaceutical company developing novel
therapeutics for the treatment of autoimmune and allergic diseases. The company
is pioneering the development of soluble Fc-gamma receptors (FcgRs), which are
recombinant autologous therapeutic proteins with a specific immunoregulatory
potential. The company's lead product SM101, a recombinant soluble FcgRIIB is in
phase II clinical development for the treatment of Primary Immune
Thrombocytopenia (ITP) and Systemic Lupus Erythematosus (SLE) and has potential
to treat Rheumatoid Arthritis (RA) and other autoimmune conditions. SuppreMol's
pipeline also includes two antibody development programs utilizing the
inhibitory effect of FcgRIIB suitable for alternative treatment strategies and
indications as well as an anti-IL-3 antibody to treat RA. SuppreMol was founded
as a spin-off from the laboratory of Prof. Dr. Robert Huber, Nobel Prize
Laureate in Chemistry 1988, at the Max Planck Institute for Biochemistry in
Martinsried, Germany. To date SuppreMol has raised ? 40.3 million through
private investors. Major shareholders in the company include MIG Fonds,
BioMedPartners AG, Santo Holding GmbH and FCP Biotech Holding GmbH along with
KfW Mittelstandsbank, Bayern Kapital GmbH, Max Planck Society, and Z-Cube.
Contact
SuppreMol GmbH
Dr. Klaus Schollmeier
Chief Executive Officer
Tel: +49 89 30 90 50 680
E-mail: info(at)suppremol.com
www.suppremol.com
Press Release PDF:
http://hugin.info/155552/R/1689453/554492.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: SuppreMol GmbH via Thomson Reuters ONE
[HUG#1689453]
Unternehmensinformation / Kurzprofil:
Datum: 02.04.2013 - 13:00 Uhr
Sprache: Deutsch
News-ID 245118
Anzahl Zeichen: 5428
contact information:
Town:
Martinsried/Munich
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 238 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"SuppreMol appoints industry expert Klaus Schollmeier as CEO"
steht unter der journalistisch-redaktionellen Verantwortung von
SuppreMol GmbH (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
